HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. - Wikidata - awgldk - TriplyDB

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

http://www.wikidata.org/entity/Q35899068

about

Clinical Development of the E75 Vaccine in Breast Cancer Immunotargeting of cancer stem cells IFN-γ Rα is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches The immune microenvironment of breast ductal carcinoma in situ.Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.Pattern response of dendritic cells in the tumor microenvironment and breast cancer Dendritic-cell-based therapeutic cancer vaccines Optimizing dendritic cell-based approaches for cancer immunotherapy Dendritic cell-based vaccines: barriers and opportunities Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.Potential use of vaccines in the primary prevention of breast cancer in high-risk patients.Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.Preclinical HER-2 Vaccines: From Rodent to Human HER-2 Immunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance.Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.Immunotherapy strategies in the treatment of breast cancer.Human dendritic cell subsets in vaccination.Exploiting dendritic cells in the development of cancer vaccines.Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.Dendritic cell-based vaccines: clinical applications in breast cancer.Targeting human dendritic cells in situ to improve vaccines.Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers.Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.Immunotherapy for the treatment of breast cancer.Mammographic features of calcifications in DCIS: correlation with oestrogen receptor and human epidermal growth factor receptor 2 status.Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ.Vaccines targeting helper T cells for cancer immunotherapy.Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.Immune modulation by dendritic-cell-based cancer vaccines.Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy.Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer

P2860

Q26745440-C8E2D89D-77F9-4C99-96F6-372C9ED968F7 Q27014031-9141A3E3-1400-4B8B-B6C2-6E900CD66EFF Q27342843-6F1D3D6D-1016-402C-9CDA-9C28C95E19EF Q28067145-388290F5-7E50-4CE6-A849-3F7198915BAC Q28077815-42CDF2FB-5941-4209-8F75-DBDA82B48ED0 Q28080472-8D92109D-00A5-4279-9853-087579C41337 Q33834968-EA3A15E1-EB9E-4FFB-8FC1-C71390FE0728 Q33926275-0DAAA6D8-8D23-4731-A8BD-B885CE22C3B0 Q33966430-4FF62A51-C344-4E0D-BCE4-2E0AF8FF11C5 Q34023724-D1A0F5FF-C38A-47C1-AAF7-55A833B764C4 Q34360094-BD0F1D2B-5CB8-41AA-A9C8-6BFB2236C252 Q34637535-CBC4A878-67F7-4261-80BB-C25563AC5AC6 Q34661797-A66A8C29-AD32-498F-A03F-B1E2FA7FDC59 Q35807188-6073EA3B-2896-4CE1-A77F-75F8568D8383 Q35826624-2C43C028-1B4F-46B5-99FA-CB2F6E0F58B1 Q36107949-3C5AE62D-C34E-4470-940C-858DE99A2E79 Q36112574-9CEE9184-E53B-4038-8567-CB1702CA9AF8 Q36449263-BE4379FF-B5AE-4C02-9EDA-6E8C540ACD1F Q36487452-8E8177A3-6EFA-45F4-B845-319CDB2BF97F Q36914661-9D770087-3BD1-4046-8EFB-E6E7B5082F19 Q37383212-3AA3D40A-5B0F-4C4D-9635-A7C85F0C30F9 Q37691212-70120A34-4BF4-4E42-9675-9F47A19A63F9 Q37709626-0A994E1E-136E-450C-B736-28223BA60AFC Q38072812-8520C418-A383-45AE-AF83-8690581CEB58 Q38110971-1F841580-8568-47AF-9FA5-EB0A7090F2E7 Q38148774-C2102DA6-DCDB-4B75-8256-1A4D410F68A5 Q38168904-B7E441EE-68E3-4158-A714-7601F38543D0 Q38206821-DDC25E4D-4160-43B9-A512-59749577C2DB Q38235001-FC568C65-503E-473B-9EAE-A4B7B96671D8 Q38244698-82F7EBDF-E682-4D51-9AC5-C3A2831E074D Q38293525-54BF0D0B-6AFF-41B2-B266-A2AC7575EEC2 Q38353772-5EE44ADC-F635-4D3B-B5F0-1131A05DF255 Q38452169-DB73C68C-A06B-45BA-A506-52BFDD6884B1 Q38648122-B92139B4-F521-44BE-999A-CB40CECE841D Q38649958-47E5D4ED-FBCB-4BA5-A9BB-9F75FFE7E3CB Q38948901-41EC4FA2-B30E-48C6-8FEF-06C875344D0C Q39147683-7FF1CBE0-439D-43C1-ADE3-3B358FCBD6A6 Q39299639-14F4B4A4-B803-4CD5-A630-6D22C773F61B Q40745788-1020D311-8EEC-49F6-ACF3-EB3A354A56EB Q41716752-3BB45459-42DD-4DED-8102-3F3A6DC3A565

P2860

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

http://www.wikidata.org/entity/Q35899068

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

HER-2 pulsed dendritic cell va ...... pact ductal carcinoma in situ.

@ast

HER-2 pulsed dendritic cell va ...... pact ductal carcinoma in situ.

@en

type

label

HER-2 pulsed dendritic cell va ...... pact ductal carcinoma in situ.

@ast

HER-2 pulsed dendritic cell va ...... pact ductal carcinoma in situ.

@en

prefLabel

HER-2 pulsed dendritic cell va ...... pact ductal carcinoma in situ.

@ast

HER-2 pulsed dendritic cell va ...... pact ductal carcinoma in situ.

@en

P1433

Q35899068-ABAE06BC-76FF-4260-87B7-4D50BD54F7C9

P1476

Q35899068-1A55D304-BACF-4F28-858B-93C253A3C558

P2093

Q35899068-08AA7ECC-EF75-4ECE-A59C-B2CF5A726D32

Q35899068-159CB459-FE23-4EBC-AAD7-59886AC838D5

Q35899068-1CC06BED-FC75-414E-BA9F-01899CD52C29

Q35899068-1E680FFA-02DB-4055-A301-A79C70C45644

Q35899068-2148E4D5-2D4C-4FC5-9EDE-7BB64E6571D1

Q35899068-2F456F31-F74D-47B7-8B74-55FF62459CEA

Q35899068-43C95D98-C700-4075-BA6A-E0A7C1E953E5

Q35899068-94C946B1-D6C4-4339-B65F-5D1CB3A0EB6B

Q35899068-C39D9279-966E-4924-AB63-F6639575A452

Q35899068-CB133FC4-F8AA-4098-979F-474CEDD2231C

P2860

Q35899068-0653D2C6-D16B-4EA5-9E20-06C804A15BFC

Q35899068-1029AE9F-FC2C-4CB1-85FE-4F128BFBD7EF

Q35899068-10C87DC2-FD3B-4F10-932A-B6AB15935917

Q35899068-13FF7C0C-E72E-4407-B531-107738DF6D58

Q35899068-159DF8D5-1584-4039-ADEE-DB4362A74E9B

Q35899068-1BD3AEED-6362-4723-91A5-C3AF2D645EB0

Q35899068-2627BB4F-EF66-444F-A3D7-70C0E71FF096

Q35899068-2768ECE9-D181-4C53-B08A-DEAB7D8BF346

Q35899068-28B6B121-5D70-49BB-8F43-6FF0C2CFB393

Q35899068-2C5697F4-CD21-4E9A-A05F-02D6529F5E6C

P304

Q35899068-E4019F03-8867-4F0A-A3CB-5868E5466E68

P31

Q35899068-5922B2CB-4251-403F-A7F0-A53468CBC751

P356

Q35899068-528396AC-3FBC-4675-BFE0-4C7379EB0A7C

P407

Q35899068-22FC4609-5929-48D6-9B8D-77E9BC7CAD5A

P433

Q35899068-C7A2F71C-C158-47EE-B2C6-0DCEAB43178C

P478

Q35899068-D97C5DF4-DF7F-421B-8391-8CF1214F7C6A

P50

Q35899068-B54E745C-DD14-4AF6-B0F8-F49B6B1F6C3A

P577

Q35899068-8E2A70E5-6696-41A4-A070-7F770BC41519

P5875

Q35899068-A107A723-E565-408B-B320-A9D055B86517

P698

Q35899068-3158DC8C-A01A-4EBF-84E8-C632FA4CBB94

P932

Q35899068-13D79691-4C72-4829-99BD-DD0B08E60FDC

P356

P1433

P1476

HER-2 pulsed dendritic cell va ...... mpact ductal carcinoma in situ

@en

P2093

Anupama Sharma

http://www.w3.org/2001/XMLSchema#string

Brian J Czerniecki

http://www.w3.org/2001/XMLSchema#string

Bruce L Levine

http://www.w3.org/2001/XMLSchema#string

Elizabeth Fitzpatrick

http://www.w3.org/2001/XMLSchema#string

Gary Koski

http://www.w3.org/2001/XMLSchema#string

Harvey Nisenbaum

http://www.w3.org/2001/XMLSchema#string

Kevin Fox

http://www.w3.org/2001/XMLSchema#string

Paul Zhang

http://www.w3.org/2001/XMLSchema#string

Robert Roses

http://www.w3.org/2001/XMLSchema#string

Rosemarie Mick

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.

Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.

Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients.

P304

4354-4362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.26734

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Susan P. Weinstein

P577

2012-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221754782

http://www.w3.org/2001/XMLSchema#string

P698

22252842

http://www.w3.org/2001/XMLSchema#string

P932

3330145

http://www.w3.org/2001/XMLSchema#string